CoImmune Announces Positive Results from Phase 1/2 Clinical Trial of Allogeneic CAR-CIK Cells in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
15 déc. 2021 08h02 HE
|
CoIMMUNE
Oral presentation at 63rd ASH Annual Meeting & Exposition shows that treatment based on company’s proprietary technology platform induced sustained responses without severe toxicities Company...
CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.
17 nov. 2021 08h00 HE
|
CoIMMUNE
DURHAM, N.C., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, announced...
CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors
15 nov. 2021 08h00 HE
|
CoIMMUNE
DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
CoImmune Announces Collaboration with Top US Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors
18 oct. 2021 08h00 HE
|
CoIMMUNE
DURHAM, N.C., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
20 sept. 2021 09h38 HE
|
CoIMMUNE
DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors
06 juil. 2021 09h16 HE
|
CoIMMUNE
DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular...
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
24 févr. 2021 09h00 HE
|
CoIMMUNE
DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid...
Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH
16 déc. 2020 14h27 HE
|
CoIMMUNE
DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim...
CoImmune, Inc. Announces Closing of $45 Million Series A Financing
10 nov. 2020 13h05 HE
|
CoIMMUNE
DURHAM, N.C., Nov. 10, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications,...
CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.
30 avr. 2020 15h55 HE
|
CoIMMUNE
DURHAM, N.C. , April 30, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic...